We detail a cross-sectional, multi-plasma biomarker characterization of the AIBL cohort samples using plasma Aβ42/40 ratio, pTau217, pTau181, GFAP, and Nf-L assays across the Alzheimer's disease (AD) continuum, and determine discriminatory performance with CNS amyloid PET imaging status.
No takes yet. Share an insight, caveat, or question.
Winslow et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: